Aegis acts as Sole Bookrunner on $1.3 Million Underwritten Public Offering for SciSparc Ltd.
- Aug 15, 2023
- 2 min read
New York, New York / GLOBE NEWSWIRE/ August 14, 2023 / Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC).
About SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
For more information, please visit https://scisparc.com
About Aegis Capital Corporation
Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research, sales and trading services to institutional and retail investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.
For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.
Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.
These press releases always read clean, but I wish they’d spell out the practical impact: how many quarters of runway does $1.3M actually buy after underwriting fees, and which study gets funded first? With clinical-stage companies, “portfolio of programs” can quickly become “spread too thin.” Not sure why, but thinking about priorities made me think of how picking a StyleLookLab approach forces you to commit to a cohesive direction instead of trying every trend at once. Would be nice to see a sharper focus statement tied to the financing.
Interesting to see how cannabinoid-focused clinical programs keep finding ways to stay funded even in a tougher market — but these smaller raises always make me wonder what the plan is for the next 12 months. Also, mixing a clinical-stage story with an e-commerce hemp product line can feel like two different investor decks stapled together. On a totally unrelated note, the “brand story vs. science story” split is kind of like how imgg turns the same input into a different style altogether. Curious which program management thinks can move the valuation needle first.
Seeing Aegis as sole bookrunner on a smaller deal like this makes me think the real story is more about keeping the company funded until the next data readout, not “growth capital” in the usual sense. The release lists a lot of programs, but it’s hard to tell which one is actually prioritized when the raise size is this limited. Random tangent: the way finance announcements get syndicated everywhere feels like how listings spread on hrefgo — same content, different audience. I’d still want to know what their projected cash runway is after fees and expenses.
The pipeline list is ambitious, but with cannabinoid-based programs it feels like the big question is always trial design and endpoints — especially for Tourette’s and agitation, where placebo effects can get messy. I also wonder how much investor appetite has shifted now that capital is tighter and small raises get scrutinized more. This kind of “what is it really?” classification problem weirdly reminds me of using a better cipher identifier tool to figure out what you’re looking at before you try to solve it. Would be helpful if the release gave a clearer sense of expected runway and near-term data timing.
Whenever I see small-cap biotech raises like this, I always wonder how much retail ends up chasing headlines without digging into dilution and burn rate. The blurb about the Amazon marketplace subsidiary is interesting, but it also makes the company feel less “pure play” than the pipeline summary suggests. Funny aside — the way people fixate on quick wins reminds me of chasing a high score in BlockBlast instead of playing the long game. I’d love to know what milestones they’re aiming to hit before the next raise.